Brought to you by Thai One On
Tue, 28 Feb 2012 09:00:00 EST (New York, NY, February 28, 2012) The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is cautiously optimistic about a remote-controlled microchip implant device that is designed to eliminate the need for regular patient self-injection of certain medications.
An article appearing on Forbes.com suggests that new microchip technology developed at the Massachusetts Institute of Technology (MIT) might help patients suffering from osteoporosis get the correct dose of medication without having to endure injections or swallow pills.
Robert Langer and Michael Cima, two MIT researchers working with the company MicroCHIPS, Inc., have developed a remote-controlled microchip implant capable of delivering prescription medications to patients. The chip, in development for about ten years, just completed its first human test, prompting researchers to claim that it 'passed with flying colors.'
The microchip implant was tested on seven women between the ages of 65 and 70 who suffer from osteoporosis. In all seven patients, the chip delivered the correct dose of medication without any adverse side effects. Some bone drugs are administered by injection, rather than in pill form like Fosamax. The idea behind the remote-controlled microchip implant is to effectively deliver an accurate dose of medication while ensuring compliance on the part of patients. Many persons cannot, or will not inject themselves with medication.
Langer commented, 'This trial demonstrates how drug[s] can be delivered through an implantable device that can be monitored and controlled remotely, providing new opportunities to improve treatment for patients and to realize the potential of telemedicine. The convergence of drug delivery and electronic technologies gives physicians a real-time connection to their patient's health, and patients are freed from the daily reminder, or burden, of disease by eliminating the need for daily injections.' Right now, the implant is only capable of being monitored within very short distances, but the researchers are currently working on its programming functions.
Despite being the most popular osteoporosis treatment on the market, Fosamax has been linked to several serious side effects. In 2004, researchers found a causal connection between Fosamax and osteonecrosis of the jaw, a condition that causes the jawbone to literally die because of a lack of blood supply. More recently, there has been a link between Fosamax and low-impact femur fractures experienced from standing height or less. Evidence is mounting that Fosamax and similar drugs prescribed to treat osteoporosis cause a dramatic increase in the risk of this kind of rare fracture to the thigh bone.
The Rottenstein Law Group advises anyone with a friend or family member who has been prescribed Fosamax or another osteoporosis drug to recommend to that person that he or she consult a physician immediately, then speak to a qualified Fosamax lawyer. The Rottenstein Law Group lawyers have a total of more than 25 years of experience fighting for the rights of clients who have suffered harm due to the negligence of powerful corporations. Affected individuals are advised to keep apprised of the latest news concerning the Fosamax femur fracture lawsuits by checking the Fosamax Femur Fracture Lawsuit Information Center for updated information. The site is equipped with easy-to-use social media features which will enable users to spread the word about the dangers of Fosamax.
About the Rottenstein Law Group
The Rottenstein Law Group is a New York-based law firm that represents clients in mass tort actions. The firm was founded by Rochelle Rottenstein, a lawyer with over two decades of experience in compassionate representation of clients in consumer product injury, mass tort, and class action law suits. For more information, please visit their Web site, or call (888) 9-ROT-LAW.
(New York, NY, February 28, 2012) The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is cautiously optimistic about a remote-controlled microchip implant device that is designed to eliminate the need for regular patient self-injection of certain medications.